| General
|
|
|
|
|
|
|
|
1. General
The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and with the Company’s Consolidated Financial Statements and Notes thereto included in the Company’s 2012 Annual Report on Form 10-K.
|
2. Ownership Interests in and Advances to Partner Companies and Funds
The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies and private equity funds.
|
June 30, 2013 |
|
|
December 31, 2012 |
|
|||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
(In thousands) (Unaudited) |
|
|||||||
Fair value |
$ | 19,363 |
|
|
$ | 20,972 |
|
|||
|
|
|
|
|
|
|
|
|||
Equity Method: |
|
|
|
|
|
|
|
|||
Partner companies |
|
98,997 |
|
|
|
102,931 |
|
|||
Private equity funds |
|
3,714 |
|
|
|
3,810 |
|
|||
|
|
102,711 |
|
|
|
106,741 |
|
|||
Cost Method: |
|
|
|
|
|
|
|
|||
Partner companies |
|
13,030 |
|
|
|
10,000 |
|
|||
Private equity funds |
|
2,484 |
|
|
|
2,634 |
|
|||
|
|
15,514 |
|
|
|
12,634 |
|
|||
|
|
|
|
|
|
|
|
|||
Advances to partner companies |
|
5,512 |
|
|
|
8,292 |
|
|||
|
|
|
|
|
|
|
|
|||
|
$ | 143,100 |
|
|
$ | 148,639 |
|
|||
|
|
|
|
|
|
|
|
|||
Loan participations receivable |
$ | 8,310 |
|
|
$ | 7,085 |
|
|||
|
|
|
|
|
|
|
|
|||
Available-for-sale securities |
$ | 18 |
|
|
$ | 58 |
|
The Company recognized impairment charges of $9.9 million and $3.7 million related to PixelOptics Inc. (“PixelOptics”) in the three months ended June 30, 2013 and 2012, respectively, which are reflected in Equity loss in the Consolidated Statements of Operations. The impairment in 2013 was based on the decision of PixelOptics to seek additional capital from independent sources as well as the Company’s decision to deploy no substantial additional capital in PixelOptics. The impairment in 2012 was based upon launch delays and related supply chain issues, as well as the pricing of a transaction between other institutional shareholders in PixelOptics.
The Company recorded impairment charges of $0.3 million and $0.7 million related to its Penn Mezzanine debt and equity participations in the three months ended June 30, 2013 and 2012, respectively, which are reflected in Other income (loss), net in the Consolidated Statements of Operations. In the three months ended June 30, 2013, the charge included $0.2 million related to loan participations and $0.1 million representing an adjustment to the fair value of the Company’s participation in warrants. In the three months ended June 30, 2012, the charge included $0.2 million related to loan participations, $0.4 million related to equity participations and $0.1 million representing an adjustment to the fair value of the Company’s participation in warrants.
The Company recognized impairment charges of $0.2 million and $0.4 million related to its interest in a legacy private equity fund in the first quarter of 2013 and 2012, respectively, which are reflected in Other income (loss), net in the Consolidated Statements of Operations.
For the three and six months ended June 30, 2013, the Company recognized an unrealized loss of $2.4 million and $1.6 million, respectively, on the mark-to-market of its holdings in NuPathe, Inc. (“NuPathe”), which is included in Other income (loss), net in the Consolidated Statements of Operations.
The following unaudited summarized results of operations for the three months ended March 31, 2013 and 2012 for PixelOptics have been compiled from the unaudited financial statements of PixelOptics.
The results of PixelOptics are reported on a one quarter lag.
|
Three Months Ended March 31, |
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
2013 |
|
|
2012 |
|
|||||
|
|
(In thousands) |
|
|||||||
|
|
(Unaudited) |
|
|||||||
Results of Operations: |
|
|
|
|
|
|
|
|||
Revenue |
$ | 539 |
|
|
$ | 307 |
|
|||
Operating loss |
$ |
(5,855 |
) |
|
$ |
(8,721 |
) |
|||
Net loss |
$ |
(7,061 |
) |
|
$ |
(9,012 |
) |
|
3. Acquisitions of Ownership Interests in Partner Companies and Funds
During the six months ended June 30, 2013, the Company funded $2.3 million for participations in loan and equity interests initiated by Penn Mezzanine. Included in this funding were $2.2 million for participation in a loan and $0.1 million for participation in equity of the borrower acquired by Penn Mezzanine.
During the six months ended June 30, 2013, the Company funded an aggregate of $5.3 million of a convertible bridge loan to PixelOptics. The Company previously deployed an aggregate of $31.6 million in PixelOptics. PixelOptics provides electronic corrective eyeglasses designed to substantially reduce or eliminate the visual distortion and other limitations associated with multifocal lenses. The Company accounts for its interest in PixelOptics under the equity method.
In June 2013, the Company deployed an additional $5.3 million into Medivo, Inc. (“Medivo”). The Company had previously acquired an interest in Medivo in November 2011 for $6.3 million. Medivo is a healthcare IT company that connects patients to a nationwide network of physicians, lab service centers and home testing services. The Company accounts for its interest in Medivo under the equity method. With respect to the June 2013 deployment, the difference between the Company’s cost and its interest in the underlying net assets of Medivo was preliminarily allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to partner companies and funds on the Consolidated Balance Sheets.
In June 2013, the Company funded $0.3 million of a convertible bridge loan to Alverix, Inc (“Alverix”). The Company had previously deployed an aggregate of $8.8 million in Alverix. Alverix provides next-generation instrument and connectivity platforms for diagnostic Point-of-Care testing. The Company accounts for its interest in Alverix under the equity method.
In May 2013, the Company funded $0.2 million of a convertible bridge loan to Hoopla Software, Inc. (“Hoopla”). The Company had previously acquired an interest in Hoopla in December 2011 for $1.3 million. Hoopla helps organizations create high performance sales cultures through software-as-a-service solutions that integrate with customer relationship management systems. The Company accounts for its interest in Hoopla under the equity method.
In March 2013, the Company deployed an additional $1.7 million into Lumesis, Inc. (“Lumesis”). The Company had previously acquired an interest in Lumesis in February 2012 for $2.2 million. Lumesis is a financial technology company that is dedicated to delivering timely data and robust analytical tools for the fixed income marketplace. The Company accounts for its interest in Lumesis under the equity method. The difference between the Company’s cost and its interest in the underlying net assets of Lumesis was allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to partner companies and funds on the Consolidated Balance Sheets.
In February 2013, the Company acquired a 6.5% ownership interest in Clutch Holdings, LLC (“Clutch”) for $0.5 million. Clutch is a mobile commerce platform that unifies applications associated with gifting, loyalty and shopping programs to improve the customer experience. The Company accounts for its interest in Clutch under the cost method.
In February 2013, the Company acquired a 27.6% ownership interest in Pneuron, Inc. (“Pneuron”) for $5.0 million. Pneuron helps enterprise companies reduce the time and cost of application development by building solutions across heterogeneous databases and applications. The Company accounts for its ownership interest in Pneuron under the equity method. The difference between the Company’s cost and its interest in the underlying net assets of Pneuron was preliminarily allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to partner companies and funds on the Consolidated Balance Sheets.
In January 2013, the Company acquired a 7.7% interest in Sotera Wireless, Inc. (“Sotera”). The Company deployed $1.3 million into Sotera and acquired additional shares from a previous investor for $1.2 million. Sotera is a medical device company that has developed a wireless patient monitoring platform that is designed to keep clinicians connected to their patients. The Company accounts for its interest in Sotera under the cost method.
|
4. Fair Value Measurements
The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on the Company’s Consolidated Balance Sheets are categorized as follows:
Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2—Include other inputs that are directly or indirectly observable in the marketplace.
Level 3—Unobservable inputs which are supported by little or no market activity.
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012:
|
Carrying |
|
|
Fair Value Measurement at June 30, 2013 |
|
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||
Cash and cash equivalents |
$ | 102,732 |
|
|
$ | 102,732 |
|
|
$ | — |
|
|
$ | — |
|
|||||||||||
Cash held in escrow |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Restricted marketable securities |
|
6 |
|
|
|
6 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Ownership interest in common stock of NuPathe |
|
15,791 |
|
|
|
15,791 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Ownership interest in warrants and options of NuPathe |
|
3,572 |
|
|
|
— |
|
|
|
— |
|
|
|
3,572 |
|
|||||||||||
Available-for-sale securities |
|
18 |
|
|
|
18 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Warrant participations |
|
417 |
|
|
|
— |
|
|
|
— |
|
|
|
417 |
|
|||||||||||
Marketable securities—held-to-maturity: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Commercial paper |
$ | 19,237 |
|
|
$ | 19,237 |
|
|
$ | — |
|
|
$ | — |
|
|||||||||||
U.S. Treasury Bills |
|
18,180 |
|
|
|
18,180 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Government agency bonds |
|
22,166 |
|
|
|
22,166 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Certificates of deposit |
|
17,794 |
|
|
|
17,794 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Total marketable securities………………………………………………… |
$ | 77,377 |
|
|
$ | 77,377 |
|
|
$ | — |
|
|
$ | — |
|
|
|
Carrying |
|
|
Fair Value Measurement at December 31, 2012 |
|
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||
Cash and cash equivalents |
$ | 66,029 |
|
|
$ | 66,029 |
|
|
$ | — |
|
|
$ | — |
|
|||||||||||
Cash held in escrow |
|
6,434 |
|
|
|
6,434 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Restricted marketable securities |
|
10 |
|
|
|
10 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Ownership interest in common stock of NuPathe |
|
8,897 |
|
|
|
8,897 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Ownership interest in preferred stock, warrants and options of NuPathe |
|
12,075 |
|
|
|
— |
|
|
|
— |
|
|
|
12,075 |
|
|||||||||||
Available-for-sale securities |
|
58 |
|
|
|
58 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Warrant participations |
|
423 |
|
|
|
— |
|
|
|
— |
|
|
|
423 |
|
|||||||||||
Marketable securities—held-to-maturity: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Commercial paper |
$ | 50,932 |
|
|
$ | 50,932 |
|
|
$ | — |
|
|
$ | — |
|
|||||||||||
U.S. Treasury Bills |
|
21,352 |
|
|
|
21,352 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Government agency bonds |
|
45,909 |
|
|
|
45,909 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Certificates of deposit |
|
21,823 |
|
|
|
21,823 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Total marketable securities………………………………………………… |
$ | 140,016 |
|
|
$ | 140,016 |
|
|
$ | — |
|
|
$ | — |
|
As of June 30, 2013, $70.2 million of marketable securities had contractual maturities which were less than one year and $7.2 million of marketable securities had contractual maturities greater than one year. Held-to-maturity securities are carried at amortized cost, which, due to the short-term maturity of these instruments, approximates fair value using quoted prices in active markets for identical assets or liabilities defined as Level 1 inputs under the fair value hierarchy.
The Company recorded an impairment charge of $9.9 million related to PixelOptics in the three months ended June 30, 2013 measured as the amount by which PixelOptics’ carrying value exceeded its estimated fair value. The fair market value of the Company’s equity ownership in PixelOptics was determined to be $3.3 million based on Level 3 inputs as defined above. The inputs and valuation techniques used included primarily an evaluation of discounted cash flows for PixelOptics.
The Company’s Penn Mezzanine warrant participations are carried at fair value. The value of the Company’s holdings in warrant participations is measured by reference to Level 3 inputs. The inputs and valuation techniques used include discounted cash flows and valuation of comparable public companies. The Company recorded an impairment charge of $0.3 million related to its Penn Mezzanine debt and equity participations in the three months ended June 30, 2013 measured as the amount by which the carrying value of the Company’s participation in the debt, equity and warrant interests acquired by Penn Mezzanine exceeded their estimated fair values.
The Company’s ownership interests in NuPathe are accounted for at fair value. In February 2013, the Company converted its 2,500 shares of preferred stock units, acquired in October 2012, into 2.5 million shares of common stock in NuPathe. The preferred stock units had been valued using Level 3 inputs. The fair value of the Company’s ownership interest in NuPathe’s common stock was measured using quoted market prices for NuPathe’s common stock as traded on the NASDAQ Capital Market, which is considered a Level 1 input under the valuation hierarchy. The fair value of the Company’s ownership interest in NuPathe’s warrants and options was measured using a Black-Scholes option pricing model, which is based on Level 3 inputs as defined above.
|
5. Convertible Debentures and Credit Arrangements
The carrying values of the Company’s convertible senior debentures were as follows:
|
June 30, 2013 |
|
|
December 31, 2012 |
|
|||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
(In thousands) |
|
|||||||
|
|
(Unaudited) |
|
|||||||
Convertible senior debentures due 2018 |
$ | 48,970 |
|
|
$ | 48,483 |
|
|||
Convertible senior debentures due 2014 |
|
29 |
|
|
|
67 |
|
|||
Convertible senior debentures due 2024 |
|
441 |
|
|
|
441 |
|
|||
|
|
49,440 |
|
|
|
48,991 |
|
|||
Less: current portion |
|
(470 |
) |
|
|
- |
|
|||
Convertible senior debentures – non current |
$ | 48,970 |
|
|
$ | 48,991 |
|
Convertible Senior Debentures due 2018
In November 2012, Safeguard issued $55.0 million principal amount of its 5.25% convertible senior debentures due 2018 (the “2018 Debentures”). Proceeds from the offering were used to repurchase substantially all of the Company’s then outstanding 10.125% convertible senior debentures due 2014 (the “2014 Debentures”). Interest on the 2018 Debentures is payable semi-annually on May 15 and November 15.
Holders of the 2018 Debentures may convert their notes prior to November 15, 2017 at their option only under the following circumstances:
during any calendar quarter commencing after the calendar quarter ending on December 31, 2012, if the last reported sale price of the common stock for at least 20 trading days during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on such trading day;
if the notes have been called for redemption; or
upon the occurrence of specified corporate events.
On or after November 15, 2017, until the close of business on the second business day immediately preceding the maturity date, holders may convert their notes at any time, regardless of whether any of the foregoing conditions has been met. Upon conversion, the Company will satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of common stock or a combination of cash and shares of our common stock, at the Company’s election.
The conversion rate of the 2018 Debentures is 55.17 shares of common stock per $1,000 principal amount of debentures, equivalent to a conversion price of approximately $18.13 per share of common stock. The closing price per share of the Company’s common stock at June 30, 2013 was $16.05.
On or after November 15, 2016, the Company may redeem for cash any of the 2018 Debentures if the last reported sale price of the Company’s common stock exceeds 140% of the conversion price for at least 20 trading days during the period of 30 consecutive trading days ending on the trading day before the date that notice of redemption is given, including the last trading day of such period. Upon any redemption of the 2018 Debentures, the Company will pay a redemption price of 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption, and additional interest, if any.
The 2018 Debenture holders have the right to require the Company to repurchase the 2018 Debentures if the Company undergoes a fundamental change, which includes the sale of all or substantially all of the Company’s common stock or assets; liquidation; dissolution; a greater than 50% change in control; the delisting of the Company’s common stock from the New York Stock Exchange or the NASDAQ Global Market (or any of their respective successors); or a substantial change in the composition of the Company’s board of directors as defined in the governing agreement. Holders may require that the Company repurchase for cash all or part of their 2018 Debentures at a fundamental change repurchase price equal to 100% of the principal amount of the debentures to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.
Because the 2018 Debentures may be settled in cash or partially in cash upon conversion, the Company separately accounts for the liability and equity components of the 2018 Debentures. The carrying amount of the liability component was determined at the transaction date by measuring the fair value of a similar liability that does not have an associated equity component. The carrying amount of the equity component represented by the embedded conversion option was determined by deducting the fair value of the liability component from the initial proceeds of the 2018 Debentures as a whole. At June 30, 2013, the fair value of the $55.0 million outstanding 2018 Debentures was approximately $60.5 million, based on the midpoint of the bid and ask prices as of such date. At June 30, 2013, the carrying amount of the equity component was $6.4 million, the principal amount of the liability component was $55.0 million, the unamortized discount was $6.0 million and the net carrying value of the liability component was $49.0 million. The Company is amortizing the excess of the face value of the 2018 Debentures over their carrying value over their term as additional interest expense using the effective interest method and recorded $0.5 million for the six months ended June 30, 2013. The effective interest rate on the 2018 Debentures is 8.7%.
Convertible Senior Debentures due 2024
In 2004, the Company issued an aggregate of $150.0 million in face value of convertible senior debentures with a stated maturity date of March 15, 2024 (the “2024 Debentures”). At June 30, 2013, the fair value of the $0.4 million outstanding 2024 Debentures approximated their carrying value, based on the midpoint of bid and ask prices as of such date. Interest on the 2024 Debentures is payable semi-annually. At the debenture holders’ option, the 2024 Debentures are convertible into the Company’s common stock through March 14, 2024, subject to certain conditions. The adjusted conversion rate of the 2024 Debentures is $43.3044 of principal amount per share. The remaining 2024 Debenture holders have the right to require the Company to repurchase the 2024 Debentures on March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their face amount, plus accrued and unpaid interest. In limited circumstances, the Company has the right to redeem all or some of the 2024 Debentures.
Convertible Senior Debentures due 2014
In March 2010, the Company issued an aggregate of $46.9 million of the 2014 Debentures. As noted above, in November 2012, the Company repurchased substantially all of the 2014 Debentures for $58.7 million plus accrued interest.
Credit Arrangements
The Company is party to a loan agreement with a commercial bank which provides it with a revolving credit facility in the maximum aggregate amount of $50 million in the form of borrowings, guarantees and issuances of letters of credit (subject to a $20 million sublimit). Actual availability under the credit facility is based on the amount of cash maintained at the bank as well as the value of the Company’s public and private partner company interests. This credit facility bears interest at the prime rate for outstanding borrowings, subject to an increase in certain circumstances. Other than for limited exceptions, the Company is required to maintain all of its depository and operating accounts and the lesser of $80 million or 75% of its investment and securities accounts at the bank. The credit facility, as amended December 21, 2012, matures on December 31, 2014. Under the credit facility, the Company provided a $6.3 million letter of credit expiring on March 19, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters which was required in connection with the sale of CompuCom Systems in 2004. Availability under the Company’s revolving credit facility at June 30, 2013 was $43.7 million.
|
6. Stock-Based Compensation
Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2013 |
|
|
2012 |
|
|
2013 |
|
|
2012 |
|
||||||||
|
|
(In thousands) |
|
|
|
(In thousands) |
|
||||||||||||
|
|
(Unaudited) |
|
|
|
(Unaudited) |
|
||||||||||||
General and administrative expense |
$ | 922 |
|
|
$ | 846 |
|
|
$ | 1,298 |
|
|
$ | 1,229 |
|
||||
|
$ | 922 |
|
|
$ | 846 |
|
|
$ | 1,298 |
|
|
$ | 1,229 |
|
The fair value of the Company’s stock-based awards to employees was estimated at the date of grant using the Black-Scholes option-pricing model. The risk-free rate was based on the U.S. Treasury yield curve in effect at the end of the quarter in which the grant occurred. The expected term of stock options granted was estimated using the historical exercise behavior of employees. Expected volatility was based on historical volatility measured using weekly price observations of the Company’s common stock for a period equal to the stock option’s expected term.
At June 30, 2013, the Company had outstanding options that vest based on three different types of vesting schedules:
1) market–based;
2) performance-based; and
3) service-based.
Market-based awards entitle participants to vest in a number of options determined by achievement by the Company of certain target market capitalization increases (measured by reference to stock price increases on a specified number of outstanding shares) over an eight-year period. The requisite service periods for the market-based awards are based on the Company’s estimate of the dates on which the market conditions will be met as determined using a Monte Carlo simulation model. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if market capitalization targets are achieved earlier than estimated. During the six months ended June 30, 2013 and 2012, respectively, the Company did not issue any market-based option awards to employees. During the six months ended June 30, 2013 and 2012, respectively, no options vested based on achievement of market capitalization targets. The Company recorded compensation expense related to market-based option awards of $0.1 million in both the three months ended June 30, 2013 and 2012, and $0.1 million and $0.2 million for the six months ended June 30, 2013 and 2012, respectively. Depending on the Company’s stock performance, the maximum number of unvested shares at June 30, 2013 attainable under these grants was 956 thousand shares.
Performance-based awards entitle participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies. Vesting may occur, if at all, once per year. The requisite service periods for the performance-based awards are based on the Company’s estimate of when the performance conditions will be met. Compensation expense is recognized for performance-based awards for which the performance condition is considered probable of achievement. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated. During the six months ended June 30, 2013 and 2012, respectively, the Company did not issue any performance-based awards to employees. During the six months ended June 30, 2013 and 2012, respectively, no performance-based awards vested. The Company recorded compensation expense related to performance-based option awards of $0.1 million for both the three months ended June 30, 2013 and 2012, and $0.2 million and $0.1 million for the six months ended June 30, 2013 and 2012, respectively. The maximum number of unvested shares at June 30, 2013 attainable under these option grants was 805 thousand shares.
All other outstanding options are service-based awards that generally vest over four years after the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based awards is the period over which the award vests. During the six months ended June 30, 2013 and 2012, respectively, the Company issued 28 thousand and 43 thousand service-based option awards to employees. The Company recorded compensation expense related to service-based option awards of $0.1 million and $0.3 million for the three months ended June 30, 2013 and 2012, and $0.2 million and $0.4 million for the six months ended June 30, 2013 and 2012, respectively.
During the six months ended June 30, 2013 and 2012, respectively, the Company issued 44 thousand and 22 thousand deferred stock units to non-employee directors for annual service grants or fees earned during the preceding quarter. Deferred stock units issued to directors in lieu of directors fees are 100% vested at the grant date; matching deferred stock units equal to 25% of directors’ fees deferred vest one year following the grant date or, if earlier, upon reaching age 65. Deferred stock units are payable in stock on a one-for-one basis. Payments related to the deferred stock units are generally distributable following termination of employment or service, death or permanent disability.
Total compensation expense for deferred stock units, performance-based stock units and restricted stock was approximately $0.6 million and $0.3 million for the three months ended June 30, 2013 and 2012, and $0.7 million and $0.5 million for the six months ended June 30, 2013 and 2012, respectively. During the six months ended June 30, 2012, the Company issued five thousand unrestricted shares to members of its advisory board, and recorded expense of $0.1 million related to these awards.
|
7. Income Taxes
The Company’s consolidated income tax benefit (expense) was $0.0 million for the three and six months ended June 30, 2013 and 2012. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the tax benefit related to the net operating losses that would have been recognized in the three and six three months ended June 30, 2013 and 2012 were offset by changes in the valuation allowance.
During the three and six months ended June 30, 2013, the Company had no material changes in uncertain tax positions.
|
9. Operating Segments
In the fourth quarter of 2012, the Company expanded its focus within the former Life Sciences segment to include companies in the HealthTech sector and renamed that segment “Healthcare.” The HealthTech sector had previously been included in the Company’s Technology segment. AdvantEdge Healthcare Solutions, a provider of physician billing and practice management services and software, which had previously been reported within the Technology segment, is now reported under the Healthcare segment. As a result of the change, the Company has restated its previously reported segment disclosure information, to include the results of AdvantEdge Healthcare Solutions within the Healthcare segment.
As of June 30, 2013, the Company held interests in 20 non-consolidated partner companies which are included in the Healthcare and Technology segments. Included in the Penn Mezzanine segment are the Company’s interests in the Penn Mezzanine management company and general partner and the Company’s participations in mezzanine loans and equity interests initiated by Penn Mezzanine.
The Company’s active partner companies by segment were as follows as of June 30, 2013:
Healthcare |
|
|
|
|
---|---|---|---|---|
Partner Company |
Safeguard Primary Ownership |
|
Accounting Method |
|
AdvantEdge Healthcare Solutions, Inc. |
40.2 | % |
|
Equity |
Alverix, Inc. |
49.2 | % |
|
Equity |
Crescendo Bioscience, Inc. |
12.6 | % |
|
Cost |
Good Start Genetics, Inc. |
30.0 | % |
|
Equity |
Medivo, Inc. |
34.5 | % |
|
Equity |
NovaSom, Inc. |
30.3 | % |
|
Equity |
NuPathe, Inc. |
16.6 | % |
|
Fair value (1) |
PixelOptics, Inc. |
24.6 | % |
|
Equity |
Putney, Inc. |
27.6 | % |
|
Equity |
Sotera Wireless, Inc. |
7.4 | % |
|
Cost |
Technology |
|
|
|
|
---|---|---|---|---|
Partner Company |
Safeguard Primary Ownership |
|
Accounting Method |
|
AppFirst, Inc. |
35.0 | % |
|
Equity |
Beyond.com, Inc. |
38.3 | % |
|
Equity |
Bridgevine, Inc. |
22.5 | % |
|
Equity |
DriveFactor, Inc. |
35.4 | % |
|
Equity |
Hoopla Software, Inc. |
25.3 | % |
|
Equity |
Lumesis, Inc. |
44.2 | % |
|
Equity |
MediaMath, Inc. |
22.2 | % |
|
Equity |
Pneuron, Inc. |
27.6 | % |
|
Equity |
Spongecell, Inc. |
23.1 | % |
|
Equity |
ThingWorx, Inc. |
39.8 | % |
|
Equity |
|
(1) The Company's ownership interest in NuPathe was accounted for as available-for-sale securities following NuPathe’s completion of an initial public offering in August 2010. In October 2012, the Company participated in a private placement of NuPathe preferred stock units, and in conjunction with this financing, the Company placed two persons on NuPathe's board of directors. As a result, the Company determined that it exercised significant influence over NuPathe which made the equity method of accounting applicable to its ownership interests. Instead, the Company elected the fair value option beginning in October 2012. Prior to August 2010, the Company accounted for NuPathe under the equity method.
As of June 30, 2013, in the Penn Mezzanine segment, the Company has a 36% ownership interest in the management company and general partner of Penn Mezzanine L.P. The Company accounts for its interest under the equity method.
Results of the Healthcare and Technology segments reflect the equity income (loss) of their respective equity method partner companies, other income (loss) associated with fair value method and cost method partner companies and the gains or losses on the sale of their respective partner companies. Results of the Penn Mezzanine segment includes interest, dividends and participation fees earned on the mezzanine interests in which the Company participates as well as equity income (loss) associated with the Company’s management company and general partner interest in the Penn Mezzanine platform.
Management evaluates the Healthcare and Technology segments’ performance based on net income (loss) which is based on the number of partner companies accounted for under the equity method, the Company’s voting ownership percentage in these partner companies and the net results of operations of these partner companies, any impairment charges or gain (loss) on the sale of equity and cost method partner companies.
Management evaluates the Penn Mezzanine segment performance based on the performance of the mezzanine interests in which the Company participates. This includes an evaluation of the current and future cash flows associated with interest and dividend payments as well as estimated losses based on evaluating known and inherent risks in the investments in which the Company participates.
Other Items include certain expenses which are not identifiable to the operations of the Company’s operating business segments. Other Items primarily consist of general and administrative expenses related to corporate operations, including employee compensation, insurance and professional fees, including legal and finance, interest income, interest expense and other income (loss) and equity income (loss) related to certain private equity fund ownership interests. Other Items also include income taxes, which are reviewed by management independent of segment results.
As of June 30, 2013 and December 31, 2012, all of the Company’s assets were located in the United States.
Segment assets in Other Items included primarily cash, cash equivalents, cash held in escrow, and marketable securities of $180.1 million and $212.5 million, at June 30, 2013 and December 31, 2012, respectively.
|
Three Months Ended June 30, 2013 |
|
|
|
|
|||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
Technology |
|
|
Penn |
|
|
Total |
|
|
Other |
|
|
Total |
|
|||||||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||||||||||||||
Operating loss |
$ | - |
|
|
$ | - |
|
|
$ |
(4 |
) |
|
$ |
(4 |
) |
|
$ |
(6,711 |
) |
|
$ |
(6,715 |
) |
|||||||||||||||
Interest income |
|
- |
|
|
|
- |
|
|
|
380 |
|
|
|
380 |
|
|
|
410 |
|
|
|
790 |
|
|||||||||||||||
Equity loss |
|
(14,850 |
) |
|
|
(3,399 |
) |
|
|
(94 |
) |
|
|
(18,343 |
) |
|
|
(57 |
) |
|
|
(18,400 |
) |
|||||||||||||||
Net loss |
|
(17,275 |
) |
|
|
(3,399 |
) |
|
|
(13 |
) |
|
|
(20,687 |
) |
|
|
(7,436 |
) |
|
|
(28,123 |
) |
|||||||||||||||
Segment Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
June 30, 2013 |
|
75,154 |
|
|
|
61,266 |
|
|
|
13,186 |
|
|
|
149,606 |
|
|
|
186,512 |
|
|
|
336,118 |
|
|||||||||||||||
December 31, 2012 |
|
83,500 |
|
|
|
58,753 |
|
|
|
12,153 |
|
|
|
154,406 |
|
|
|
219,738 |
|
|
|
374,144 |
|
|
|
Three Months Ended June 30, 2012 |
|
|
|
|
|||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
Technology |
|
|
Penn |
|
|
Total |
|
|
Other |
|
|
Total |
|
|||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||||||||||
Operating loss |
$ | - |
|
|
$ | - |
|
|
$ |
(2 |
) |
|
$ |
(2 |
) |
|
$ |
(5,146 |
) |
|
$ |
(5,148 |
) |
|||||||||||
Interest income |
|
- |
|
|
|
- |
|
|
|
277 |
|
|
|
277 |
|
|
|
318 |
|
|
|
595 |
|
|||||||||||
Equity loss |
|
(8,820 |
) |
|
|
(56 |
) |
|
|
(69 |
) |
|
|
(8,945 |
) |
|
|
(2 |
) |
|
|
(8,947 |
) |
|||||||||||
Net loss |
|
(3,270 |
) |
|
|
(56 |
) |
|
|
(533 |
) |
|
|
(3,859 |
) |
|
|
(6,278 |
) |
|
|
(10,137 |
) |
|
Six Months Ended June 30, 2013 |
|
|
|
|
|||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
Technology |
|
|
Penn |
|
|
Total |
|
|
Other |
|
|
Total |
|
|||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||||||||||
Operating loss |
$ | - |
|
|
$ | - |
|
|
$ |
(9 |
) |
|
$ |
(9 |
) |
|
$ |
(12,080 |
) |
|
$ |
(12,089 |
) |
|||||||||||
Interest income |
|
- |
|
|
|
- |
|
|
|
724 |
|
|
|
724 |
|
|
|
800 |
|
|
|
1,524 |
|
|||||||||||
Equity (loss) income |
|
(20,750 |
) |
|
|
(4,500 |
) |
|
|
(164 |
) |
|
|
(25,414 |
) |
|
|
27 |
|
|
|
(25,387 |
) |
|||||||||||
Net (loss) income |
|
(22,340 |
) |
|
|
(4,500 |
) |
|
|
328 |
|
|
|
(26,512 |
) |
|
|
(13,550 |
) |
|
|
(40,062 |
) |
|
|
Six Months Ended June 30, 2012 |
|
|
|
|
||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
Technology |
|
|
Penn |
|
|
Total |
|
|
Other |
|
|
Total |
|
||||||||||||||||||||||
|
|
(In thousands) |
|
||||||||||||||||||||||||||||||||||||
|
|
(Unaudited) |
|
||||||||||||||||||||||||||||||||||||
Operating loss |
$ | - |
|
|
$ | - |
|
|
$ |
(4 |
) |
|
$ |
(4 |
) |
|
$ |
(9,887 |
) |
|
$ |
(9,891 |
) |
||||||||||||||||
Interest income |
|
- |
|
|
|
- |
|
|
|
848 |
|
|
|
848 |
|
|
|
646 |
|
|
|
1,494 |
|
||||||||||||||||
Equity loss |
|
(15,159 |
) |
|
|
(1,045 |
) |
|
|
(188 |
) |
|
|
(16,392 |
) |
|
|
(3 |
) |
|
|
(16,395 |
) |
||||||||||||||||
Net loss |
|
(6,180 |
) |
|
|
(1,045 |
) |
|
|
(83 |
) |
|
|
(7,308 |
) |
|
|
(12,489 |
) |
|
|
(19,797 |
) |
|
10. Commitments and Contingencies
The Company and its partner companies are involved in various claims and legal actions arising in the ordinary course of business. While in the current opinion of the Company the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operations, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its partner companies. The Company records costs associated with legal fees as such services are rendered.
Not including the Laureate Biopharma, Inc. lease guaranty described below, the Company had outstanding guarantees of $3.8 million at June 30, 2013.
The Company has committed capital of approximately $0.1 million to a private equity fund. This commitment is expected to be funded during the next 12 months.
Under certain circumstances, the Company may be required to return a portion or all the distributions it received as a general partner of a private equity fund (“clawback”). The maximum clawback the Company could be required to return due to its general partner interest is approximately $1.3 million, of which $1.0 million was reflected in Accrued expenses and other current liabilities and $0.3 million was reflected in Other long-term liabilities on the Consolidated Balance Sheet at June 30, 2013. The Company’s ownership in the fund is 19%. The clawback liability is joint and several; therefore the Company may be required to fund the clawback for other general partners should they default. The Company believes its potential liability due to the possibility of default by other general partners is remote.
In connection with the Company’s May 2008 sale of its equity and debt interests in Acsis, Inc., Alliance Consulting Group Associates, Inc., Laureate Biopharma, Inc., ProModel Corporation and Neuronyx, Inc. (the “Bundle Transaction”), an aggregate of $6.4 million of the gross proceeds of the sale were placed in escrow pending the expiration of a predetermined notification period, subject to possible extension in the event of a claim against the escrowed amounts. On April 25, 2009, the purchaser in the Bundle Transaction notified the Company of claims being asserted against the entire escrowed amounts. In April 2013, the case was tried on the merits and the verdict in the case denied the purchaser’s claims against the escrowed funds. The escrow funds were released to the Company in June 2013.
The Company remains guarantor of Laureate Biopharma, Inc.’s Princeton, New Jersey facility lease. Such guarantee may extend through the lease expiration in 2016 under certain circumstances. However, the Company is entitled to indemnification in connection with the continuation of such guaranty. As of June 30, 2013, scheduled lease payments to be made by Laureate Biopharma, Inc. over the remaining lease term equaled $4.2 million.
In October 2001, the Company entered into an agreement with its former Chairman and Chief Executive Officer to provide for annual payments of $0.65 million per year and certain health care and other benefits for life. The related current liability of $0.8 million was included in Accrued expenses and other current liabilities and the long-term portion of $2.8 million was included in Other long-term liabilities on the Consolidated Balance Sheet at June 30, 2013.
The Company provided a $6.3 million letter of credit expiring on March 19, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters as required in connection with the sale of CompuCom Systems in 2004.
The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under the agreements was approximately $2.4 million at June 30, 2013. During the three months ended June 30, 2013, a Company executive terminated his employment for “good reason.” As a result of the termination, the Company recognized a severance charge of $0.9 million which is recorded in Accrued compensation and benefits on the Consolidated Balance Sheet at June 30, 2013.
|
The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies and private equity funds.
|
June 30, 2013 |
|
|
December 31, 2012 |
|
|||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
(In thousands) (Unaudited) |
|
|||||||
Fair value |
$ | 19,363 |
|
|
$ | 20,972 |
|
|||
|
|
|
|
|
|
|
|
|||
Equity Method: |
|
|
|
|
|
|
|
|||
Partner companies |
|
98,997 |
|
|
|
102,931 |
|
|||
Private equity funds |
|
3,714 |
|
|
|
3,810 |
|
|||
|
|
102,711 |
|
|
|
106,741 |
|
|||
Cost Method: |
|
|
|
|
|
|
|
|||
Partner companies |
|
13,030 |
|
|
|
10,000 |
|
|||
Private equity funds |
|
2,484 |
|
|
|
2,634 |
|
|||
|
|
15,514 |
|
|
|
12,634 |
|
|||
|
|
|
|
|
|
|
|
|||
Advances to partner companies |
|
5,512 |
|
|
|
8,292 |
|
|||
|
|
|
|
|
|
|
|
|||
|
$ | 143,100 |
|
|
$ | 148,639 |
|
|||
|
|
|
|
|
|
|
|
|||
Loan participations receivable |
$ | 8,310 |
|
|
$ | 7,085 |
|
|||
|
|
|
|
|
|
|
|
|||
Available-for-sale securities |
$ | 18 |
|
|
$ | 58 |
|
The results of PixelOptics are reported on a one quarter lag.
|
Three Months Ended March 31, |
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
2013 |
|
|
2012 |
|
|||||
|
|
(In thousands) |
|
|||||||
|
|
(Unaudited) |
|
|||||||
Results of Operations: |
|
|
|
|
|
|
|
|||
Revenue |
$ | 539 |
|
|
$ | 307 |
|
|||
Operating loss |
$ |
(5,855 |
) |
|
$ |
(8,721 |
) |
|||
Net loss |
$ |
(7,061 |
) |
|
$ |
(9,012 |
) |
|
The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012:
|
Carrying |
|
|
Fair Value Measurement at June 30, 2013 |
|
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||
Cash and cash equivalents |
$ | 102,732 |
|
|
$ | 102,732 |
|
|
$ | — |
|
|
$ | — |
|
|||||||||||
Cash held in escrow |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Restricted marketable securities |
|
6 |
|
|
|
6 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Ownership interest in common stock of NuPathe |
|
15,791 |
|
|
|
15,791 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Ownership interest in warrants and options of NuPathe |
|
3,572 |
|
|
|
— |
|
|
|
— |
|
|
|
3,572 |
|
|||||||||||
Available-for-sale securities |
|
18 |
|
|
|
18 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Warrant participations |
|
417 |
|
|
|
— |
|
|
|
— |
|
|
|
417 |
|
|||||||||||
Marketable securities—held-to-maturity: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Commercial paper |
$ | 19,237 |
|
|
$ | 19,237 |
|
|
$ | — |
|
|
$ | — |
|
|||||||||||
U.S. Treasury Bills |
|
18,180 |
|
|
|
18,180 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Government agency bonds |
|
22,166 |
|
|
|
22,166 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Certificates of deposit |
|
17,794 |
|
|
|
17,794 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Total marketable securities………………………………………………… |
$ | 77,377 |
|
|
$ | 77,377 |
|
|
$ | — |
|
|
$ | — |
|
|
|
Carrying |
|
|
Fair Value Measurement at December 31, 2012 |
|
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||
Cash and cash equivalents |
$ | 66,029 |
|
|
$ | 66,029 |
|
|
$ | — |
|
|
$ | — |
|
|||||||||||
Cash held in escrow |
|
6,434 |
|
|
|
6,434 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Restricted marketable securities |
|
10 |
|
|
|
10 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Ownership interest in common stock of NuPathe |
|
8,897 |
|
|
|
8,897 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Ownership interest in preferred stock, warrants and options of NuPathe |
|
12,075 |
|
|
|
— |
|
|
|
— |
|
|
|
12,075 |
|
|||||||||||
Available-for-sale securities |
|
58 |
|
|
|
58 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Warrant participations |
|
423 |
|
|
|
— |
|
|
|
— |
|
|
|
423 |
|
|||||||||||
Marketable securities—held-to-maturity: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Commercial paper |
$ | 50,932 |
|
|
$ | 50,932 |
|
|
$ | — |
|
|
$ | — |
|
|||||||||||
U.S. Treasury Bills |
|
21,352 |
|
|
|
21,352 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Government agency bonds |
|
45,909 |
|
|
|
45,909 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Certificates of deposit |
|
21,823 |
|
|
|
21,823 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Total marketable securities………………………………………………… |
$ | 140,016 |
|
|
$ | 140,016 |
|
|
$ | — |
|
|
$ | — |
|
|
The carrying values of the Company’s convertible senior debentures were as follows:
|
June 30, 2013 |
|
|
December 31, 2012 |
|
|||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
(In thousands) |
|
|||||||
|
|
(Unaudited) |
|
|||||||
Convertible senior debentures due 2018 |
$ | 48,970 |
|
|
$ | 48,483 |
|
|||
Convertible senior debentures due 2014 |
|
29 |
|
|
|
67 |
|
|||
Convertible senior debentures due 2024 |
|
441 |
|
|
|
441 |
|
|||
|
|
49,440 |
|
|
|
48,991 |
|
|||
Less: current portion |
|
(470 |
) |
|
|
- |
|
|||
Convertible senior debentures – non current |
$ | 48,970 |
|
|
$ | 48,991 |
|
|
Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2013 |
|
|
2012 |
|
|
2013 |
|
|
2012 |
|
||||||||
|
|
(In thousands) |
|
|
|
(In thousands) |
|
||||||||||||
|
|
(Unaudited) |
|
|
|
(Unaudited) |
|
||||||||||||
General and administrative expense |
$ | 922 |
|
|
$ | 846 |
|
|
$ | 1,298 |
|
|
$ | 1,229 |
|
||||
|
$ | 922 |
|
|
$ | 846 |
|
|
$ | 1,298 |
|
|
$ | 1,229 |
|
|
The Company’s active partner companies by segment were as follows as of June 30, 2013:
Healthcare |
|
|
|
|
---|---|---|---|---|
Partner Company |
Safeguard Primary Ownership |
|
Accounting Method |
|
AdvantEdge Healthcare Solutions, Inc. |
40.2 | % |
|
Equity |
Alverix, Inc. |
49.2 | % |
|
Equity |
Crescendo Bioscience, Inc. |
12.6 | % |
|
Cost |
Good Start Genetics, Inc. |
30.0 | % |
|
Equity |
Medivo, Inc. |
34.5 | % |
|
Equity |
NovaSom, Inc. |
30.3 | % |
|
Equity |
NuPathe, Inc. |
16.6 | % |
|
Fair value (1) |
PixelOptics, Inc. |
24.6 | % |
|
Equity |
Putney, Inc. |
27.6 | % |
|
Equity |
Sotera Wireless, Inc. |
7.4 | % |
|
Cost |
Technology |
|
|
|
|
---|---|---|---|---|
Partner Company |
Safeguard Primary Ownership |
|
Accounting Method |
|
AppFirst, Inc. |
35.0 | % |
|
Equity |
Beyond.com, Inc. |
38.3 | % |
|
Equity |
Bridgevine, Inc. |
22.5 | % |
|
Equity |
DriveFactor, Inc. |
35.4 | % |
|
Equity |
Hoopla Software, Inc. |
25.3 | % |
|
Equity |
Lumesis, Inc. |
44.2 | % |
|
Equity |
MediaMath, Inc. |
22.2 | % |
|
Equity |
Pneuron, Inc. |
27.6 | % |
|
Equity |
Spongecell, Inc. |
23.1 | % |
|
Equity |
ThingWorx, Inc. |
39.8 | % |
|
Equity |
|
(1) The Company's ownership interest in NuPathe was accounted for as available-for-sale securities following NuPathe’s completion of an initial public offering in August 2010. In October 2012, the Company participated in a private placement of NuPathe preferred stock units, and in conjunction with this financing, the Company placed two persons on NuPathe's board of directors. As a result, the Company determined that it exercised significant influence over NuPathe which made the equity method of accounting applicable to its ownership interests. Instead, the Company elected the fair value option beginning in October 2012. Prior to August 2010, the Company accounted for NuPathe under the equity method.
|
Three Months Ended June 30, 2013 |
|
|
|
|
|||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
Technology |
|
|
Penn |
|
|
Total |
|
|
Other |
|
|
Total |
|
|||||||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||||||||||||||
Operating loss |
$ | - |
|
|
$ | - |
|
|
$ |
(4 |
) |
|
$ |
(4 |
) |
|
$ |
(6,711 |
) |
|
$ |
(6,715 |
) |
|||||||||||||||
Interest income |
|
- |
|
|
|
- |
|
|
|
380 |
|
|
|
380 |
|
|
|
410 |
|
|
|
790 |
|
|||||||||||||||
Equity loss |
|
(14,850 |
) |
|
|
(3,399 |
) |
|
|
(94 |
) |
|
|
(18,343 |
) |
|
|
(57 |
) |
|
|
(18,400 |
) |
|||||||||||||||
Net loss |
|
(17,275 |
) |
|
|
(3,399 |
) |
|
|
(13 |
) |
|
|
(20,687 |
) |
|
|
(7,436 |
) |
|
|
(28,123 |
) |
|||||||||||||||
Segment Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
June 30, 2013 |
|
75,154 |
|
|
|
61,266 |
|
|
|
13,186 |
|
|
|
149,606 |
|
|
|
186,512 |
|
|
|
336,118 |
|
|||||||||||||||
December 31, 2012 |
|
83,500 |
|
|
|
58,753 |
|
|
|
12,153 |
|
|
|
154,406 |
|
|
|
219,738 |
|
|
|
374,144 |
|
|
|
Three Months Ended June 30, 2012 |
|
|
|
|
|||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
Technology |
|
|
Penn |
|
|
Total |
|
|
Other |
|
|
Total |
|
|||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||||||||||
Operating loss |
$ | - |
|
|
$ | - |
|
|
$ |
(2 |
) |
|
$ |
(2 |
) |
|
$ |
(5,146 |
) |
|
$ |
(5,148 |
) |
|||||||||||
Interest income |
|
- |
|
|
|
- |
|
|
|
277 |
|
|
|
277 |
|
|
|
318 |
|
|
|
595 |
|
|||||||||||
Equity loss |
|
(8,820 |
) |
|
|
(56 |
) |
|
|
(69 |
) |
|
|
(8,945 |
) |
|
|
(2 |
) |
|
|
(8,947 |
) |
|||||||||||
Net loss |
|
(3,270 |
) |
|
|
(56 |
) |
|
|
(533 |
) |
|
|
(3,859 |
) |
|
|
(6,278 |
) |
|
|
(10,137 |
) |
|
Six Months Ended June 30, 2013 |
|
|
|
|
|||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
Technology |
|
|
Penn |
|
|
Total |
|
|
Other |
|
|
Total |
|
|||||||||||||||||
|
|
(In thousands) |
|
|||||||||||||||||||||||||||||||
|
|
(Unaudited) |
|
|||||||||||||||||||||||||||||||
Operating loss |
$ | - |
|
|
$ | - |
|
|
$ |
(9 |
) |
|
$ |
(9 |
) |
|
$ |
(12,080 |
) |
|
$ |
(12,089 |
) |
|||||||||||
Interest income |
|
- |
|
|
|
- |
|
|
|
724 |
|
|
|
724 |
|
|
|
800 |
|
|
|
1,524 |
|
|||||||||||
Equity (loss) income |
|
(20,750 |
) |
|
|
(4,500 |
) |
|
|
(164 |
) |
|
|
(25,414 |
) |
|
|
27 |
|
|
|
(25,387 |
) |
|||||||||||
Net (loss) income |
|
(22,340 |
) |
|
|
(4,500 |
) |
|
|
328 |
|
|
|
(26,512 |
) |
|
|
(13,550 |
) |
|
|
(40,062 |
) |
|
|
Six Months Ended June 30, 2012 |
|
|
|
|
||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
Technology |
|
|
Penn |
|
|
Total |
|
|
Other |
|
|
Total |
|
||||||||||||||||||||||
|
|
(In thousands) |
|
||||||||||||||||||||||||||||||||||||
|
|
(Unaudited) |
|
||||||||||||||||||||||||||||||||||||
Operating loss |
$ | - |
|
|
$ | - |
|
|
$ |
(4 |
) |
|
$ |
(4 |
) |
|
$ |
(9,887 |
) |
|
$ |
(9,891 |
) |
||||||||||||||||
Interest income |
|
- |
|
|
|
- |
|
|
|
848 |
|
|
|
848 |
|
|
|
646 |
|
|
|
1,494 |
|
||||||||||||||||
Equity loss |
|
(15,159 |
) |
|
|
(1,045 |
) |
|
|
(188 |
) |
|
|
(16,392 |
) |
|
|
(3 |
) |
|
|
(16,395 |
) |
||||||||||||||||
Net loss |
|
(6,180 |
) |
|
|
(1,045 |
) |
|
|
(83 |
) |
|
|
(7,308 |
) |
|
|
(12,489 |
) |
|
|
(19,797 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|